The Grumpy Husband’s Guide To Getting Rich

I was having lunch with a buddy in Palo Alto last week when he mentioned that his wife’s doctor just prescribed her Ozempic.

“Cost me eight hundred bucks for a month’s supply,” he grumbled, stabbing his salad.

That’s when it hit me. We’re living through one of those rare moments when an entire industry gets completely reshuffled, and most people are too busy counting calories to notice the real money being made.

The weight loss drug revolution isn’t just changing waistlines, it’s minting fortunes.

Curiously, the Danish company that basically started this whole craze just got absolutely crushed by the market, and nobody seems to care that you can now buy Novo Nordisk (NVO) at fire sale prices.

The story of Novo Nordisk’s recent struggles reads like a perfect storm of competitive pressure and regulatory headaches.

Since the fourth quarter of 2024, the company has been battered by a relentless stream of negative news, while its main competitor, Eli Lilly (LLY), seemingly couldn’t put a foot wrong.

First came the CagriSema phase three results that, while positive, fell short of the street’s lofty expectations.

Then the semaglutide supply issues opened the door for compounders to muscle in on their territory, essentially creating knockoff versions of Ozempic and Wegovy while Novo Nordisk scrambled to meet demand.

Meanwhile, Eli Lilly was busy grabbing market share with their tirzepatide drugs Mounjaro and Zepbound, even publishing head-to-head trial data showing their drug’s superiority over semaglutide.

Add in Eli Lilly’s impressive pipeline advances with orforglipron, their first oral GLP-1 drug, and you had a perfect recipe for investor pessimism around Novo Nordisk.

The company’s stock has dropped 17% since May, and management shocked everyone in late July by cutting their full-year revenue and operating guidance.

But here’s where the narrative gets exciting.

August brought the first real crack in Eli Lilly’s armor when their orforglipron obesity results came in underwhelming, giving Novo Nordisk some much-needed breathing room.

More importantly, the FDA approved semaglutide for MASH treatment just last week, opening up an entirely new revenue stream for Wegovy.

Now, let’s talk about what MASH means in real dollars.

Competitor Madrigal (MDGL) estimates there are 1.5 million diagnosed MASH patients in the United States, but Novo Nordisk believes the actual patient population could be as high as 16 million.

Even if you take the conservative estimate, we’re looking at a multibillion-dollar market opportunity.

Madrigal is already seeing impressive numbers from just 23,000 patients on their MASH drug Rezdiffra, generating over $200 million in quarterly net sales.

Granted, Rezdiffra commands a much higher price than Wegovy, but volume has a way of making up for lower per-unit pricing, especially when you’re talking about treating potentially millions of patients.

The compounder situation, while frustrating, is ultimately a temporary headache.

Novo Nordisk is taking these companies to court, arguing that continued compounding is illegal now that the official shortage has ended. Yes, some compounders are trying to dance around patent protections by claiming “personalized dosing,” but patent law doesn’t typically smile on such creative interpretations.

This legal battle will resolve itself in Novo Nordisk’s favor, it’s just a matter of time.

Looking at the bigger picture, both Novo Nordisk and Eli Lilly are barely scratching the surface in international markets.

The obesity drug expansion has been primarily focused on the United States due to supply constraints, but those days are ending.

International rollout represents massive untapped revenue potential, and Novo Nordisk’s global infrastructure gives it significant advantages in many markets.

The pipeline story remains compelling despite recent setbacks. Beyond CagriSema, which honestly still looks like a solid obesity treatment compared to current semaglutide, the company is advancing high-dose semaglutide that already beat the approved dose in head-to-head trials.

They’re moving oral and subcutaneous amycretin into phase three trials, advancing cagrilintide as monotherapy, and we should see phase one results from their tri-agonist candidate this quarter.

That tri-agonist could potentially rival Eli Lilly’s retatrutide, creating a competitive dynamic that looks very different from today’s narrative.

Perhaps most importantly, Novo Nordisk has a fortress balance sheet with substantial capacity for business development. While their internal pipeline outside obesity and diabetes needs work, their financial resources position them perfectly to acquire promising candidates or entire companies. In biotech, deep pockets often matter more than perfect timing.

The direct-to-consumer angle also deserves attention.

The company just announced a partnership with GoodRx to offer Ozempic and Wegovy at $499 per month for self-paying patients.

While that price point might not drive massive adoption initially, it signals management’s willingness to explore new distribution channels and pricing strategies.

When I look at Novo Nordisk today, I see a company that’s been unfairly punished by a series of unfortunate timing coinciding with a competitor’s hot streak.

The fundamentals remain strong, the addressable markets are enormous, and the recent FDA approval for MASH treatment provides a concrete new growth driver.

This feels like one of those moments where buying the dip makes perfect sense. And who knows? Maybe the next time I’m having lunch in Palo Alto, my buddy will be complaining about how much money he should have made buying Novo Nordisk stock instead of griping about his wife’s prescription costs.

That eight-hundred-dollar monthly bill might just turn into the best investment tip he never took.